Company intelligence / Profile preview

HD Biologics

Shanghai, Shanghai, Chinatakeda.com ↗

Ownership: Private
Employees: ~500
Development stage: Other

Overview

HD Biosciences is a leading preclinical CRO providing drug discovery services including target validation, hit identification and confirmation, lead discovery and optimization, in vivo pharmacology models for various indications such as metabolic disease and oncology. The company does not develop its own clinical-stage assets but supports global pharma/biotech R&D pipelines with high-quality preclinical data.

Therapeutic areas: Metabolic DisordersOncologyImmunologyGastroenterologyNeurology
Modalities: AntibodyAntibody-drug conjugateSmall moleculeGene therapyCell therapy
Industry: Drug Discovery Services

Partnerships

Organon/Akzo Nobeleight of the world’s ten largest pharmaceutical companies as clients/partnersWuXi AppTec group partnerships

Beyond the preview

Go deeper on HD Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HD Biologics.

Explore the full profile